

Final - February 16, 2012

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30333

February 22-23, 2012

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
<u>Wednesday, February 22 2012</u>		
8:00 <u>Welcome & Introductions</u>		Dr. Carol Baker (ACIP Chair) Dr. Larry Pickering (ACIP Executive Secretary; CDC)
8:30 <u>Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine</u>		
· Introduction		Dr. Mark Sawyer (ACIP, WG Chair)
· Update: resurgence of pertussis disease in the United States		Dr. Thomas Clark (CDC/NCIRD)
· Pertussis in older adults in the United States		Dr. Anna Acosta (CDC/NCIRD)
· Cost effectiveness of Tdap substitution for Td in prevention of pertussis in adults 65 years and older	Information & Discussion	Dr. Anna Acosta (CDC/NCIRD)
· Cost effectiveness analysis for Boostrix in adults 65 years of age and older		Ms. Shanthy Krishnarajah (Head, US Health Outcomes, GSK)
· Safety and immunogenicity of Tdap in persons 65 years of age and older		Dr. Jennifer Liang (CDC/NCIRD)
· Public comment		
· Proposed recommendation for use of Tdap in persons 65 years and older	<u>Vote</u>	Dr. Jennifer Liang (CDC/NCIRD)
10:30 <i>Break</i>		
11:00 <u>Influenza</u>		
· Introduction		Dr. Wendy Keitel (ACIP, WG Chair)
· Update: Influenza activity and vaccines		Dr. Lisa Grohskopf (CDC/NCIRD)
· Antiviral medications	Information & Discussion	Dr. Timothy Uyeki (CDC/NCIRD)
· Future activities		Dr. Lisa Grohskopf (CDC/NCIRD)
· Recommendations (reiteration of recommendation for annual vaccination for all 6 months of age and older)		Dr. Lisa Grohskopf (CDC/NCIRD)
12:00 <i>Lunch</i>		
1:30 <u>13-valent Pneumococcal Conjugate Vaccine (PCV13)</u>		
· Introduction		Dr. Nancy Bennett (ACIP, WG Chair)
· Pneumococcal conjugate vaccine for adults 50 years of age or older: background review of data, and GRADE		Dr. Tamara Pilishvili (CDC/NCIRD)
· Pneumococcal conjugate vaccine for adults with immunocompromising conditions: background, review of data and GRADE	Information & Discussion	Dr. Kathleen Dooling (CDC/NCIRD)
3:30 <i>Break</i>		
4:00 <u>Hepatitis B Vaccine</u>		
· Introduction		Dr. Mark Sawyer (ACIP, WG Chair)
· Ensuring hepatitis B protection for remotely vaccinated health-care personnel; overview of issues; ACIP requests for information	Information & Discussion	Dr. Sarah Schillie (CDC/NCHHSTP)
4:30 <u>Vaccine Supply</u>	Information	Dr. Jeanne Santoli (CDC/NCIRD)
4:45 <u>Public Comment</u>		
5:00 <u>Adjourn</u>		

Final - February 16, 2012

Thursday, February 23, 2012

8:00 Unfinished Business

Dr. Carol Baker (Chair, ACIP)

8:15 Agency Updates

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NVPO, NIH Information CDC and *Ex officio* members

8:30 Meningococcal Vaccines

· Introduction Dr. Cody Meissner (ACIP, WG Chair)
· GRADE (Grading of Evidence) assessment for MenACWY-D Information & Discussion Dr. Elizabeth Briere (CDC/NCIRD)
(Menactra) in children 9-23 months of age
· Updates to the Meningococcal Vaccines Statement Dr. Amanda Cohn (CDC/NCIRD)

10:00 Break

10:30 Measles, Mumps, Rubella (MMR) Vaccine

· Introduction Dr. Jon Temte (ACIP, WG Chair)
· Update: measles/rubella elimination consultation and documentation Dr. Mark Papania (CDC/NCIRD)
· Epidemiology of mumps in the United States
· Impact of a third dose of MMR vaccine on the course of a mumps outbreak in an orthodox Jewish community Information & Discussion Mr. Albert Barskey (CDC/NCIRD)
Dr. Preeta Kutty (CDC/NCIRD)
· Impact of a third dose of MMR vaccine on mumps outbreak in Guam and economic impact of the outbreak Ms. Amy Parker Fiebelkorn (CDC/NCIRD)
· Summary of issues and discussion Dr. Huong McLean (CDC/NCIRD)

12:15 Public Comment

12:30 Adjourn

Acronyms

GRADE	Grading of Recommendations Assessment, Development and Evaluation
MenACWY-D	Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
NCCDPHP	National Center for Chronic Disease Prevention and Health Promotion
NCEZID	National Center for Emerging and Zoonotic Infectious
NCHHSTP	National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
NCIRD	National Center for Immunization and Respiratory Diseases
TBD	To be determined
Tdap	Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
WG	Work Group